AU Patent

AU2019420189A1 — Ketamine derivatives and compositions thereof

Assigned to XWPharma Ltd · Expires 2021-07-29 · 5y expired

What this patent protects

Ketamine derivatives and pharmaceutical compositons thereof are disclosed. When administered orally the ketamine derivatives provide increased bioavailability of ketamine in the systemic circulation. The ketamine derivatives can be used to treat neurological diseases, psychologic…

USPTO Abstract

Ketamine derivatives and pharmaceutical compositons thereof are disclosed. When administered orally the ketamine derivatives provide increased bioavailability of ketamine in the systemic circulation. The ketamine derivatives can be used to treat neurological diseases, psychological diseases and pain.

Drugs covered by this patent

Patent Metadata

Patent number
AU2019420189A1
Jurisdiction
AU
Classification
—
Expires
2021-07-29
Drug substance claim
No
Drug product claim
No
Assignee
XWPharma Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.